News: FDA delays the verification requirements for salable returned drugs
In an announcement made by the U.S. Food and Drug Administration (FDA), it declares final guidance explaining that it will delay the verification requirements for salable returned drugs. It further explains that in a way it will enforce the Drug Supply Chain Security Act (DSCSA), which will implement a thorough verification of the product identifier of the saleable returned drugs by the wholesale distributors before they bring it back in distribution.
As per the agency, other stakeholders raised their concerns stating that there must be the implementation of the electronic systems to enable verification of the product identifier of the returned drugs that can be sold. However, the FDA resists from taking any action against the wholesale distributors, who fail to verify the product identifier until November of 2020.